dc.contributor.author | Young, Megan K | |
dc.contributor.author | Ng, Shu-Kay | |
dc.contributor.author | Nimmo, Graeme R | |
dc.contributor.author | Cripps, Allan W | |
dc.date.accessioned | 2019-07-04T12:34:50Z | |
dc.date.available | 2019-07-04T12:34:50Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 1742-5255 | |
dc.identifier.doi | 10.1080/17425255.2018.1484449 | |
dc.identifier.uri | http://hdl.handle.net/10072/383194 | |
dc.description.abstract | Background: It is unclear whether recommended doses of intramuscular polyvalent immune globulin are optimal for both effectiveness and efficiency of disease prevention when administered post-exposure to measles and rubella.
Methods: The peak concentration and decay of disease-specific antibodies after intramuscular dosing of polyvalent immune globulin in adults were modeled using published pharmacokinetic parameters and product disease-specific antibody concentrations. Models simulated dosing according to current Australian guidelines, then adjusted the dose in clinically relevant increments to estimate the optimal dose of disease-specific immunoglobulins for post-exposure prophylaxis of nonimmune individuals against measles and rubella. Optimal dosing assumed a target serum concentration of disease-specific antibodies of the correlate of protection plus a 10% margin of error at an incubation period.
Results: Current Australian guidelines appeared to underdose a measles-naïve subpopulation. The optimal dose of measles-specific antibodies was 17.5 IU/kg assuming 75% bioavailability and 25.5 IU/kg assuming 50% bioavailability. Current Australian guidelines recommend 520 IU/kg rubella antibodies for an 80-kg individual. This model suggests that 13 IU/kg is more than sufficient.
Conclusions: The recommended dose of intramuscular polyvalent immune globulin should be increased following measles exposure and decreased following rubella exposure for recommended subgroups. These models may be adapted for use internationally. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | TAYLOR & FRANCIS LTD | |
dc.relation.ispartofpagefrom | 663 | |
dc.relation.ispartofpageto | 669 | |
dc.relation.ispartofissue | 7 | |
dc.relation.ispartofjournal | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | |
dc.relation.ispartofvolume | 14 | |
dc.subject.fieldofresearch | Pharmacology and pharmaceutical sciences | |
dc.subject.fieldofresearchcode | 3214 | |
dc.title | The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Ng, Shu Kay Angus | |
gro.griffith.author | Cripps, Allan W. | |